Aug. 5 at 12:42 PM
$CSTL Key Takeaways from earnings:
Castle Biosciences reported a surprising EPS of
$0.15, beating the forecast by a wide margin.
Revenue for Q2 reached
$86.2 million, exceeding expectations and contributing to a positive market reaction.
The company raised its full-year revenue guidance, signaling confidence in future growth.
Company Performance
Castle Biosciences demonstrated robust performance in Q2 2025, despite a slight year-over-year decrease in revenue. The company capitalized on strong growth in its key product lines, such as TissueCypher, which saw a 92% year-over-year increase in test reports. These results position Castle Biosciences favorably against industry trends, highlighting its leadership in dermatologic and gastrointestinal testing.
Financial Highlights
Revenue:
$86.2 million (1% decrease YoY)
Earnings per share:
$0.15 (exceeding forecast of -
$0.51)
Adjusted EBITDA:
$10.4 million
Cash, cash equivalents, and marketable securities:
$275.9 million https://www.investing.com/news/transcripts/earnings-call-transcript-castle-biosciences-q2-2025-beats-eps-forecast-4169015
